



Financial Tear Sheet

Corporate Profile

Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that are designed to selectively target and modulate the activity of specific proteins implicated in various disease states. The Company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus, or HBV.

Primary IR Contact

Jonathan Freve
Chief Financial Officer,
Treasurer and Secretary
Phone: 508-473-5993

Stock Information

SBPH (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$13.33
Change (%)	▲ 0.33 (2.54%)
Volume	115,767
52 Week Low	\$6.31
Market Cap	\$125,651,753
Rolling EPS	-2.13
PE Ratio	0
Shares Outstanding	9,426,238

Data as of 06/23/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
06/23/17	8-K
06/23/17	424B5

06/21/17	8-K
06/21/17	424B5

Recent News & Upcoming Events

06/22/17 - 9:00 a.m. There are currently no events scheduled.
Spring Bank Pharmaceuticals Prices \$37.5 Million
Public Offering of Common Stock
06/21/17 - 4:00 p.m.
Spring Bank Pharmaceuticals Announces Proposed
Public Offering of Common Stock
06/07/17 - 7:01 a.m.
Spring Bank Provides Update on its Next-Generation
STING Platform and Announces Publication of an
Abstract at ASCO Related to its Lead STING Agonist
Candidate, SB 11285